Your browser doesn't support javascript.
loading
Radiation effects on development of HER2-positive breast carcinomas.
Castiglioni, Fabio; Terenziani, Monica; Carcangiu, Maria Luisa; Miliano, Raffaella; Aiello, Piera; Bertola, Lorenzo; Triulzi, Tiziana; Gasparini, Patrizia; Camerini, Tiziana; Sozzi, Gabriella; Fossati-Bellani, Franca; Ménard, Sylvie; Tagliabue, Elda.
Afiliação
  • Castiglioni F; Molecular Targeting Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
Clin Cancer Res ; 13(1): 46-51, 2007 Jan 01.
Article em En | MEDLINE | ID: mdl-17200337
ABSTRACT

PURPOSE:

Neither hormone-related nor genetics risk factors have been associated with the development of highly proliferative HER2-positive breast carcinomas. Because the majority of HER2-positive tumors present the amplification of the oncogene, we asked whether genomic instability triggered by irradiation might be involved in the induction of HER2-overexpressing breast carcinomas. EXPERIMENTAL

DESIGN:

Sixty-six infiltrating breast carcinomas from patients treated with radiation therapy for Hodgkin's lymphoma or other pediatric solid tumors and a control series of 61 consecutive sporadic breast tumors were analyzed by immunohistochemistry for HER2 expression with HercepTest. A panel of antibodies against estrogen receptor, progesterone receptor, c-kit, cytokeratin 5/6, p53, and ki67 antigen was also used to identify differentiation subsets and molecular characteristics of the analyzed breast carcinomas.

RESULTS:

Although no differences between the two tumor series were found with respect to HER2 expression scored 2+ and 3+, the percentage of 3+ HER2-positive tumors was significantly higher in patients irradiated during breast maturation compared with patients irradiated after breast maturation (35.3% versus 12.5%, P = 0.046). In the latter group, 52.5% of the breast carcinomas showed basal-like differentiation (estrogen receptor, progesterone receptor, and HER2 negative) versus only 5.9% in the group irradiated during breast development (P < 0.0001). Analysis adjusted for age confirmed the significant increase in basal-like tumor development in patients irradiated within 4 years of menarche, but also showed that the differences between patients irradiated before and after puberty in HER2 3+ tumor frequencies are due to age-related differences in HER2 3+ tumor onset.

CONCLUSION:

Together, our data indicate that the development of HER2-positive tumors correlates with timing rather than type of carcinogenic hits and provide clear evidence that radiation is a risk factor for breast carcinomas showing basal-like differentiation.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mama / Neoplasias da Mama / Doença de Hodgkin / Regulação Neoplásica da Expressão Gênica / Receptor ErbB-2 / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2007 Tipo de documento: Article País de afiliação: Itália
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mama / Neoplasias da Mama / Doença de Hodgkin / Regulação Neoplásica da Expressão Gênica / Receptor ErbB-2 / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2007 Tipo de documento: Article País de afiliação: Itália